Target intelligence / Profile preview

Intestinal mucosal immune and barrier system

Molecular classification
Other
01

Overview

The intestinal mucosal immune and barrier system is a complex, multi-layered defense structure essential for maintaining host homeostasis by separating the internal environment from luminal contents, including pathogens, toxins, and dietary antigens (Vancamelbeke & Vermeire, 2017). It comprises a physical barrier—consisting of the mucus layer, a single layer of epithelial cells, and intercellular tight junctions—and a functional immunological barrier known as the gut-associated lymphoid tissue (GALT) (Turner, 2009). This system facilitates the selective absorption of nutrients and water while actively preventing the translocation of harmful microorganisms and pro-inflammatory molecules into the systemic circulation (Okumura & Takeda, 2017). Dysregulation of this barrier, often referred to as "leaky gut," is a central pathogenic feature in diseases such as inflammatory bowel disease (IBD), celiac disease, and systemic inflammatory response syndrome (Mowat & Agace, 2014). Pharmacological interventions typically target specific molecular components within this system, such as cytokine signaling pathways or lymphocyte trafficking receptors, to restore barrier integrity and dampen chronic mucosal inflammation (Vancamelbeke & Vermeire, 2017).

Other names
Gut barrierIntestinal mucosal barrierMucosal immune systemGut-associated lymphoid tissueGALTIntestinal epithelial barrier
02

Mechanism of action

Modulation of inflammatory cytokine pathways (e.g., TNF-alpha inhibition), stabilization of epithelial tight junctions to reduce permeability, and regulation of mucosal lymphocyte trafficking to the gut (Vancamelbeke & Vermeire, 2017).

03

Biological functions

Immune responseBarrier functionHomeostasisNutrient absorptionMicrobiota regulation
04

Disease associations

Inflammatory bowel diseaseCrohn's diseaseUlcerative colitisCeliac diseaseIrritable bowel syndromeSepsisFood allergy
05

Safety considerations

Increased risk of opportunistic infectionsSystemic immunosuppressionPotential for mucosal healing delayDisruption of commensal microbiota balance
06

Interacting drugs

Infliximab

6 more in the full profile.

07

Biomarkers

Fecal calprotectinSerum zonulinSecretory IgACitrullineIntestinal fatty acid-binding protein (I-FABP)

Beyond the preview

Go deeper on Intestinal mucosal immune and barrier system.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intestinal mucosal immune and barrier system.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call